Adaptive Biotechnologies and Johnson & Johnson subsidiary Janssen have agreed on a collaboration to assess the effectiveness of Janssen's Darzalex for multiple myeloma through minimal residual disease measurement using Adaptive's NGS-based ClonoSeq assay. Janssen will provide Adaptive development with funding and potential future milestone payments, as well as an upfront technology access payment of an undisclosed amount.
Adaptive Biotechnologies enters Dx partnership with Janssen
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.